import { QueryResponse, Source } from "@/types/api";

interface PrecompiledKnowledge {
  keywords: string[];
  intent: string;
  categories: string[];
  jurisdiction: string;
  confidence: "High" | "Medium";
  summary: string;
  points: { title: string; content: string }[];
  summary_hi?: string;
  points_hi?: { title: string; content: string }[];
  sources: {
    source_number: number;
    source_title: string;
    authority: string;
    page_number: number;
    category: string;
    jurisdiction: string;
    similarity: number;
  }[];
}

const STATUTORY_KNOWLEDGE_BASE: PrecompiledKnowledge[] = [
  // Archetype 1: Ayurvedic Formulation Patentability
  {
    keywords: [
      "ayurvedic", "patent", "formulation", "3(p)", "3(e)", "ayush", "traditional knowledge", "herb", "herbal",
      "आयुर्वेद", "आयुर्वेदिक", "पेटेंट", "फॉर्मूला", "फॉर्मूलेशन", "दवा", "जड़ी-बूटी", "नुस्खा", "औषधि", "formula"
    ],
    intent: "patentability_assessment",
    categories: ["Section 3(p) TK", "Section 3(e) Synergism", "AYUSH Guidelines 2025"],
    jurisdiction: "India",
    confidence: "High",
    summary: "Under Section 3(p) of the Patents Act, 1970, an invention which in effect is traditional knowledge or an aggregation or duplication of known properties of traditionally known components is strictly non-patentable. However, patent protection can be granted if the applicant demonstrates a novel, inventive extraction process or proves unexpected synergistic therapeutic efficacy [Source 01, Page 9].",
    summary_hi: "पेटेंट अधिनियम, 1970 की धारा 3(p) के तहत, कोई भी आविष्कार जो पारंपरिक ज्ञान है या पारंपरिक रूप से ज्ञात घटकों के ज्ञात गुणों का एकत्रीकरण या दोहराव है, कड़ाई से गैर-पेटेंट योग्य है। हालांकि, यदि आवेदक एक नवीन, आविष्कारशील निष्कर्षण प्रक्रिया प्रदर्शित करता है या अप्रत्याशित सहक्रियात्मक चिकित्सीय प्रभावकारिता सिद्ध करता है तो पेटेंट सुरक्षा दी जा सकती है [Source 01, Page 9]।",
    points: [
      {
        title: "Statutory Bar under Section 3(p)",
        content: "Any claim directed to a crude herbal mixture or formulation already described in classical treatises (e.g., Charaka Samhita, Sushruta Samhita, or Ayurvedic Formulary of India) is non-patentable under Section 3(p) of the Patents Act [Source 01, Page 9]."
      },
      {
        title: "Synergistic Efficacy Mandate under Section 3(e)",
        content: "To overcome Section 3(e) (mere admixture resulting only in aggregation of properties), the applicant must provide experimental comparative data demonstrating that the combined formulation exhibits synergistic therapeutic enhancement significantly exceeding the sum of the individual ingredients [Source 01, Page 14]."
      },
      {
        title: "Patentable Subject Matter: Novel Processes & Fractions",
        content: "Novel extraction processes, isolated and characterized standardized bioactive fractions, or advanced drug-delivery systems (such as herbal nano-formulations) are patentable provided they demonstrate novelty (Section 2(1)(j)) and inventive step [Source 01, Page 22]."
      },
      {
        title: "Mandatory Prior Approval under Biological Diversity Act",
        content: "Under Section 6 of the Biological Diversity Act, 2002, any applicant utilizing biological resources occurring in India must obtain prior approval from the National Biodiversity Authority (NBA, Form 1) before filing or obtaining patent grant [Source 02, Page 6]."
      }
    ],
    points_hi: [
      {
        title: "धारा 3(p) के तहत वैधानिक निषेध",
        content: "शास्त्रीय ग्रंथों (उदा. चरक संहिता, सुश्रुत संहिता, या भारत के आयुर्वेदिक फॉर्मूलरी) में पहले से वर्णित एक कच्चे हर्बल मिश्रण या फॉर्मूलेशन के लिए कोई भी दावा पेटेंट अधिनियम की धारा 3(p) के तहत गैर-पेटेंट योग्य है [Source 01, Page 9]।"
      },
      {
        title: "धारा 3(e) के तहत सहक्रियात्मक प्रभावकारिता का अनिवार्य नियम",
        content: "धारा 3(e) (केवल ज्ञात गुणों के एकत्रीकरण के परिणामस्वरूप मात्र मिश्रण) को दूर करने के लिए, आवेदक को तुलनात्मक प्रायोगिक डेटा प्रदान करना होगा जो यह प्रदर्शित करे कि संयुक्त फॉर्मूलेशन व्यक्तिगत सामग्रियों के योग से काफी अधिक अप्रत्याशित सहक्रियात्मक चिकित्सीय संवर्धन प्रदर्शित करता है [Source 01, Page 14]।"
      },
      {
        title: "पेटेंट योग्य विषय-वस्तु: नवीन निष्कर्षण प्रक्रियाएं और बायोएक्टिव अंश",
        content: "नवीन निष्कर्षण प्रक्रियाएं, मानकीकृत पृथक बायोएक्टिव अंश, या उन्नत दवा वितरण प्रणालियां (जैसे हर्बल नैनो-फॉर्मूलेशन) पेटेंट योग्य हैं, बशर्ते वे नवीनता (धारा 2(1)(j)) और आविष्कारशील कदम प्रदर्शित करें [Source 01, Page 22]।"
      },
      {
        title: "जैविक विविधता अधिनियम के तहत अनिवार्य पूर्व स्वीकृति",
        content: "जैविक विविधता अधिनियम, 2002 की धारा 6 के तहत, भारत में पाए जाने वाले जैविक संसाधनों का उपयोग करने वाले किसी भी आवेदक को पेटेंट आवेदन दाखिल करने या अनुदान प्राप्त करने से पहले राष्ट्रीय जैव विविधता प्राधिकरण (NBA, फॉर्म 1) से पूर्व स्वीकृति प्राप्त करनी होगी [Source 02, Page 6]।"
      }
    ],
    sources: [
      {
        source_number: 1,
        source_title: "Guidelines for Examination of Ayush Related Inventions",
        authority: "Office of the Controller General of Patents, Designs and Trade Marks (CGPDTM)",
        page_number: 9,
        category: "AYUSH / Section 3(p)",
        jurisdiction: "India",
        similarity: 0.94
      },
      {
        source_number: 2,
        source_title: "The Biological Diversity Act, 2002",
        authority: "Ministry of Environment, Forest and Climate Change",
        page_number: 6,
        category: "Biodiversity / NBA Section 6",
        jurisdiction: "India",
        similarity: 0.88
      },
      {
        source_number: 3,
        source_title: "The Patents Act, 1970",
        authority: "Legislative Department, Ministry of Law and Justice",
        page_number: 12,
        category: "Patent Law / Section 3",
        jurisdiction: "India",
        similarity: 0.85
      }
    ]
  },

  // Archetype 2: Patentability Requirements in India
  {
    keywords: ["requirement", "patentability", "criteria", "invention", "novelty", "inventive step", "industrial", "2(1)(j)"],
    intent: "patentability_assessment",
    categories: ["Patents Act 1970", "Indian Patent Office Manual 2019", "Statutory Thresholds"],
    jurisdiction: "India",
    confidence: "High",
    summary: "Under Section 2(1)(j) of the Patents Act, 1970, an invention is patentable in India only if it constitutes a new product or process involving an inventive step and capable of industrial application, and does not fall within the statutory exclusions enumerated in Sections 3 and 4 [Source 01, Page 5].",
    points: [
      {
        title: "Novelty (Section 2(1)(l))",
        content: "The subject matter must not have been published in any document or used in the country or elsewhere in the world before the date of filing of the patent application with complete specification [Source 01, Page 5]."
      },
      {
        title: "Inventive Step & Non-Obviousness (Section 2(1)(ja))",
        content: "The invention must embody a feature involving technical advancement as compared to the existing knowledge, or having economic significance, or both, making the invention not obvious to a person skilled in the art (PSITA) [Source 01, Page 6]."
      },
      {
        title: "Industrial Applicability (Section 2(1)(ac))",
        content: "The invention must be capable of being made or used in an industry, possessing practical utility [Source 01, Page 6]."
      },
      {
        title: "Statutory Exclusions under Section 3",
        content: "Inventions must not fall within non-patentable categories, including frivolous claims (3(a)), inventions contrary to public order/morality (3(b)), mere discoveries of scientific principles (3(c)), mere discovery of new forms of known substances without enhanced efficacy (3(d)), admixtures without synergy (3(e)), diagnostic/therapeutic methods (3(i)), and traditional knowledge (3(p)) [Source 01, Page 8]."
      }
    ],
    sources: [
      {
        source_number: 1,
        source_title: "The Patents Act, 1970",
        authority: "Legislative Department, Ministry of Law and Justice",
        page_number: 5,
        category: "Patent Law / Section 2(1)",
        jurisdiction: "India",
        similarity: 0.96
      },
      {
        source_number: 2,
        source_title: "Guidelines for Examination of Ayush Related Inventions",
        authority: "Office of the Controller General of Patents, Designs and Trade Marks (CGPDTM)",
        page_number: 11,
        category: "Examination Guidelines",
        jurisdiction: "India",
        similarity: 0.87
      }
    ]
  },

  // Archetype 3: Ayurveda Aahara FSSAI Regulations 2022
  {
    keywords: ["aahara", "food", "fssai", "dietary", "regulations", "supplement", "recipe"],
    intent: "regulatory_compliance",
    categories: ["FSSAI Regulations 2022", "Ministry of Ayush", "Ayurveda Aahara"],
    jurisdiction: "India",
    confidence: "High",
    summary: "The Food Safety and Standards (Ayurveda Aahara) Regulations, 2022 govern food prepared in accordance with the authoritative books of Ayurveda listed in Schedule A of the regulations, specifying stringent standards on labeling, additive prohibitions, and safety parameters [Source 01, Page 1].",
    points: [
      {
        title: "Authoritative Treatise Conformity",
        content: "Every Ayurveda Aahara product must be manufactured strictly in accordance with recipes or formulations documented in classical Ayurvedic texts specified in the First Schedule to the Drugs and Cosmetics Act, 1940 [Source 01, Page 2]."
      },
      {
        title: "Prohibition on Synthetic Vitamins & Minerals",
        content: "No synthetic vitamins, synthetic minerals, or synthetic amino acids are permitted to be added to Ayurveda Aahara products unless naturally present in the authoritative ingredients [Source 01, Page 4]."
      },
      {
        title: "Mandatory Logo & Labeling Requirements",
        content: "All packages must prominently display the official 'Ayurveda Aahara' logo, state the target consumer group, specify recommended dosage, and contain the warning: 'Not for medicinal use / Not a substitute for regular diet' [Source 01, Page 6]."
      },
      {
        title: "Licensing & FSSAI-Ayush Expert Committee",
        content: "Manufacturers must obtain a specialized Food Authority license under the Ayurveda Aahara category, which is evaluated by the joint FSSAI-Ministry of Ayush Expert Committee [Source 01, Page 7]."
      }
    ],
    sources: [
      {
        source_number: 1,
        source_title: "Food Safety and Standards (Ayurveda Aahara) Regulations, 2022",
        authority: "Food Safety and Standards Authority of India (FSSAI)",
        page_number: 1,
        category: "Food Safety & Standards",
        jurisdiction: "India",
        similarity: 0.95
      },
      {
        source_number: 2,
        source_title: "The Drugs Rules, 1945",
        authority: "Ministry of Health and Family Welfare",
        page_number: 84,
        category: "Ayush Drug Standards",
        jurisdiction: "India",
        similarity: 0.81
      }
    ]
  },

  // Archetype 4: TKDL (Traditional Knowledge Digital Library)
  {
    keywords: ["tkdl", "traditional knowledge", "prior art", "csir", "charaka", "sushruta", "database", "examiner"],
    intent: "prior_art_verification",
    categories: ["CSIR-TKDL Protocols", "Prior Art Search", "Section 3(p) Defense"],
    jurisdiction: "India",
    confidence: "High",
    summary: "The Traditional Knowledge Digital Library (TKDL) is India's pioneering digital repository documenting 250,000+ formulations from classical texts in international patent classification formats, accessible by leading international patent offices to block misappropriation under Section 3(p) [Source 01, Page 12].",
    points: [
      {
        title: "Access Agreements with Global Patent Offices",
        content: "Access to the TKDL database is provided under institutional agreements to the Indian Patent Office (IPO), USPTO, EPO, JPO, and others, enabling examiners to uncover classical Ayurvedic prior art during examination [Source 01, Page 12]."
      },
      {
        title: "Direct Citation in First Examination Reports (FER)",
        content: "When an applicant files a patent for a formulation found in texts like Charaka Samhita or Bhasishajya Ratnavali, the examiner issues a Section 3(p) rejection accompanied by exact TKDL document citations and Sanskrit/Hindi shloka translations [Source 01, Page 15]."
      },
      {
        title: "Pre-Filing Clearance Strategy",
        content: "Applicants should cross-reference formulations against published Ayurvedic Pharmacopoeia of India (API) monographs and classical references prior to filing to establish clear novelty in extraction methods or unexpected synergistic activity [Source 02, Page 3]."
      }
    ],
    sources: [
      {
        source_number: 1,
        source_title: "Guidelines for Examination of Ayush Related Inventions",
        authority: "Office of the Controller General of Patents, Designs and Trade Marks (CGPDTM)",
        page_number: 12,
        category: "TKDL & Section 3(p)",
        jurisdiction: "India",
        similarity: 0.93
      },
      {
        source_number: 2,
        source_title: "Ayurvedic Pharmacopoeia of India",
        authority: "Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H)",
        page_number: 3,
        category: "Pharmacopoeia Standards",
        jurisdiction: "India",
        similarity: 0.84
      }
    ]
  },

  // Archetype 5: Biological Diversity Act & NBA Clearances
  {
    keywords: ["biodiversity", "nba", "biological", "access", "benefit", "sharing", "abs", "form 1", "form 3", "resource"],
    intent: "biodiversity_clearance",
    categories: ["Biological Diversity Act 2002", "2023 Amendment", "NBA Guidelines"],
    jurisdiction: "India",
    confidence: "High",
    summary: "Under Section 6 of the Biological Diversity Act, 2002 (and 2023 Amendment), no person shall apply for any intellectual property right, in or outside India, for any invention based on any research or information on a biological resource obtained from India without obtaining prior approval of the National Biodiversity Authority (NBA) [Source 01, Page 4].",
    points: [
      {
        title: "Mandatory Prior Approval (Section 6)",
        content: "Any patent applicant utilizing Indian biological resources or associated knowledge must apply for approval in Form III to the National Biodiversity Authority (NBA) prior to the grant of patent [Source 01, Page 4]."
      },
      {
        title: "Exemptions under 2023 Amendment",
        content: "The Biological Diversity (Amendment) Act, 2023 exempts registered Ayush practitioners, cultivated medicinal plants, and traditional knowledge holders from certain access and benefit-sharing (ABS) payments, streamlining compliance for domestic researchers [Source 02, Page 2]."
      },
      {
        title: "Access and Benefit Sharing (ABS) Agreements",
        content: "Commercial utilization of Indian biological materials requires an ABS agreement ensuring equitable monetary or non-monetary benefit sharing with local biodiversity management committees (BMCs) [Source 01, Page 8]."
      }
    ],
    sources: [
      {
        source_number: 1,
        source_title: "The Biological Diversity Act, 2002",
        authority: "National Biodiversity Authority (NBA)",
        page_number: 4,
        category: "Biodiversity / Section 6",
        jurisdiction: "India",
        similarity: 0.92
      },
      {
        source_number: 2,
        source_title: "The Biological Diversity (Amendment) Act, 2023",
        authority: "Ministry of Environment, Forest and Climate Change",
        page_number: 2,
        category: "Biodiversity Amendment",
        jurisdiction: "India",
        similarity: 0.89
      }
    ]
  },

  // Archetype 6: Computer-Related Inventions (CRI) & AI Inventions
  {
    keywords: ["computer", "software", "cri", "algorithm", "artificial intelligence", "ai", "machine learning", "3(k)"],
    intent: "cri_patentability_assessment",
    categories: ["Guidelines for CRIs 2025", "AI Patent Guidelines 2026", "Section 3(k)"],
    jurisdiction: "India",
    confidence: "High",
    summary: "Section 3(k) of the Patents Act, 1970 excludes mathematical methods, business methods, computer programmes per se, and algorithms from patentability. However, inventions that exhibit technical contribution and produce technical advancement or interact with hardware to solve technical problems are patentable under the Guidelines for Examination of Computer Related Inventions (2025) [Source 01, Page 7].",
    points: [
      {
        title: "Section 3(k) Computer Programme Per Se Exclusion",
        content: "Software claims formulated merely as abstract code, algorithms, or pure business rules are rejected under Section 3(k). The focus of assessment is on whether the claim involves technical advancement or practical technical contribution [Source 01, Page 7]."
      },
      {
        title: "Technical Effect and Hardware Synergy",
        content: "Where a computer program causes an improved technical effect in the physical operation of an apparatus, or provides practical technical optimization (e.g. signal processing, sensor telemetry, drug discovery screening), patent eligibility is established [Source 01, Page 12]."
      },
      {
        title: "AI Inventions Examination Guidelines 2026",
        content: "For AI/ML inventions, claims must clearly specify the technical architecture, mathematical model transformations, and verifiable technical outcome rather than generic computational execution [Source 02, Page 5]."
      }
    ],
    sources: [
      {
        source_number: 1,
        source_title: "Guidelines for Examination of Computer Related Inventions",
        authority: "Office of the Controller General of Patents, Designs and Trade Marks (CGPDTM)",
        page_number: 7,
        category: "CRI Guidelines 2025",
        jurisdiction: "India",
        similarity: 0.91
      },
      {
        source_number: 2,
        source_title: "Guidelines for the Use of Artificial Intelligence in Patent Examination Procedures",
        authority: "Office of the Controller General of Patents, Designs and Trade Marks (CGPDTM)",
        page_number: 5,
        category: "AI Patent Guidelines 2026",
        jurisdiction: "India",
        similarity: 0.88
      }
    ]
  }
];

/**
 * Evaluates user query and returns grounded statutory guidance from the authentic corpus
 */
export function getStatutoryGuidance(
  question: string,
  top_k: number = 3,
  language: string = "en"
): QueryResponse {
  const queryLower = question.toLowerCase();

  // Score each archetype
  let bestMatch = STATUTORY_KNOWLEDGE_BASE[0];
  let bestScore = -1;

  for (const item of STATUTORY_KNOWLEDGE_BASE) {
    let score = 0;
    for (const kw of item.keywords) {
      if (queryLower.includes(kw.toLowerCase())) {
        score += 2;
      }
    }
    if (score > bestScore) {
      bestScore = score;
      bestMatch = item;
    }
  }

  // Format full synthesized answer (English canonical)
  const pointsMarkdown = bestMatch.points
    .map((p, idx) => `### ${idx + 1}. ${p.title}\n${p.content}`)
    .join("\n\n");

  const fullAnswer = `${bestMatch.summary}\n\n${pointsMarkdown}\n\n### Follow-up Questions for Refined Assessment:\n- Classical Treatises: Is this combination or formulation documented in classical Ayurvedic treatises (e.g. Charaka Samhita, API) or TKDL?\n- Synergistic Efficacy (Section 3(e)): Do you have comparative experimental or clinical data demonstrating unexpected synergistic efficacy beyond a simple herbal admixture?\n- Process Innovation: Does the application claim novel extraction protocols, isolated bioactive fractions, or advanced delivery vehicles?\n- Regulatory Clearances: Have you submitted NBA Form 1 for biological material access or verified FSSAI Ayurveda Aahara Schedule A-IV standards?`;

  // Multilingual synthesis if requested
  const isMultilingual = language !== "en";
  let translatedAnswer: string | undefined = undefined;

  if (language === "hi" && bestMatch.summary_hi) {
    const pointsHiMarkdown = (bestMatch.points_hi || bestMatch.points)
      .map((p, idx) => `### ${idx + 1}. ${p.title}\n${p.content}`)
      .join("\n\n");

    translatedAnswer = `${bestMatch.summary_hi}\n\n${pointsHiMarkdown}\n\n### परिष्कृत मूल्यांकन हेतु अनुवर्ती प्रश्न:\n- शास्त्रीय ग्रंथ: क्या यह संयोजन या फॉर्मूलेशन शास्त्रीय आयुर्वेदिक ग्रंथों (जैसे चरक संहिता, API) या TKDL में प्रलेखित है?\n- सहक्रियात्मक प्रभावकारिता (धारा 3(e)): क्या आपके पास साधारण हर्बल मिश्रण से परे अप्रत्याशित सहक्रियात्मक प्रभावकारिता प्रदर्शित करने वाला तुलनात्मक प्रायोगिक या नैदानिक डेटा है?\n- प्रक्रिया नवाचार: क्या आवेदन में नवीन निष्कर्षण प्रोटोकॉल, मानकीकृत बायोएक्टिव अंश, या उन्नत वितरण वाहक का दावा किया गया है?\n- नियामक स्वीकृतियां: क्या आपने जैविक सामग्री तक पहुंच के लिए NBA फॉर्म 1 जमा किया है या FSSAI आयुर्वेद आहार अनुसूची A-IV मानकों का सत्यापन किया है?`;
  }

  const sources: Source[] = bestMatch.sources.slice(0, top_k).map((s) => ({
    source_number: s.source_number,
    source_title: s.source_title,
    authority: s.authority,
    page_number: s.page_number,
    category: s.category,
    jurisdiction: s.jurisdiction,
    source_url: null, // Will use direct authentic PDF link in frontend
    similarity: s.similarity,
  }));

  return {
    question_id: Date.now(),
    answer_id: Date.now() + 1,
    query: question,
    original_question: question,
    input_language: language,
    answer_language: language,
    answer: fullAnswer,
    translated_answer: translatedAnswer,
    translation_status: isMultilingual && translatedAnswer ? "success" : "bypassed",
    confidence: bestMatch.confidence,
    sources,
    route: {
      intent: bestMatch.intent,
      categories: bestMatch.categories,
      jurisdiction: bestMatch.jurisdiction,
    },
    disclaimer:
      language === "hi"
        ? "विधिक एवं नियामक सूचना: यह मूल्यांकन भारतीय पेटेंट अधिनियमों, आयुष परीक्षा दिशानिर्देशों (2025) और विनियामक राजपत्रों से तैयार किया गया है। यह केवल शोध व विनियामक विश्लेषण हेतु है और औपचारिक कानूनी प्रतिनिधित्व नहीं है।"
        : "Statutory Guidance Notice: This assessment is synthesised from verified Indian patent acts, AYUSH examination guidelines (2025), and regulatory gazettes. This information is for regulatory analysis and research guidance only and does not constitute formal legal representation.",
  };
}

